Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insertion of metal carbenes into the anilinic N-H bond of unprotected aminobenzenesulfonamides delivers low nanomolar inhibitors of human carbonic anhydrase IX and XII isoforms.
Sharonova T, Paramonova P, Kalinin S, Bunev A, Gasanov RЕ, Nocentini A, Sharoyko V, Tennikova TB, Dar'in D, Supuran CT, Krasavin M. Sharonova T, et al. Among authors: bunev a. Eur J Med Chem. 2021 Jun 5;218:113352. doi: 10.1016/j.ejmech.2021.113352. Epub 2021 Mar 16. Eur J Med Chem. 2021. PMID: 33774343
Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
Dar'in D, Kantin G, Kalinin S, Sharonova T, Bunev A, Ostapenko GI, Nocentini A, Sharoyko V, Supuran CT, Krasavin M. Dar'in D, et al. Among authors: bunev a. Eur J Med Chem. 2021 Oct 15;222:113589. doi: 10.1016/j.ejmech.2021.113589. Epub 2021 Jun 10. Eur J Med Chem. 2021. PMID: 34147910
Corrigendum to "Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent" [J. Med. Chem. 222 (2021) 113589].
Dar'in D, Kantin G, Kalinin S, Sharonova T, Bunev A, Ostapenko GI, Nocentini A, Sharoyko V, Supuran CT, Krasavin M. Dar'in D, et al. Among authors: bunev a. Eur J Med Chem. 2021 Dec 5;225:113788. doi: 10.1016/j.ejmech.2021.113788. Epub 2021 Aug 23. Eur J Med Chem. 2021. PMID: 34438125 No abstract available.
Replacing the phthalimide core in thalidomide with benzotriazole.
Krasavin M, Bubyrev A, Kazantsev A, Heim C, Maiwald S, Zhukovsky D, Dar'in D, Hartmann MD, Bunev A. Krasavin M, et al. Among authors: bunev a. J Enzyme Inhib Med Chem. 2022 Dec;37(1):527-530. doi: 10.1080/14756366.2021.2024525. J Enzyme Inhib Med Chem. 2022. PMID: 35220840 Free PMC article.
Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines.
Krasavin M, Adamchik M, Bubyrev A, Heim C, Maiwald S, Zhukovsky D, Zhmurov P, Bunev A, Hartmann MD. Krasavin M, et al. Among authors: bunev a. Eur J Med Chem. 2023 Jan 15;246:114990. doi: 10.1016/j.ejmech.2022.114990. Epub 2022 Dec 1. Eur J Med Chem. 2023. PMID: 36476642
38 results